Concentrations of piperacillin-tazobactam in human jaw and hip bone

Journal of Cranio-Maxillofacial Surgery

Volumn 36, Issue 8, 2008, Pages 468-472

  Al Nawas, Bilal ^a   Kinzig Schippers, Marion ^b   Soergel, Fritz ^b   Shah, Pramod M ^c  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Institute for Biomedical and Pharmaceutical Research   (Germany)

^c NONE

Author keywords

bone; concentration; iliac crest; mandible; piperacillin; tazobactam

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG BONE LEVEL; DRUG PENETRATION; FEMALE; HIP; HUMAN; HUMAN TISSUE; MALE; MANDIBLE; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; DRUG COMBINATIONS; FEMALE; HUMANS; JAW; MALE; MIDDLE AGED; PELVIC BONES; PENICILLANIC ACID; PIPERACILLIN; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 54349088682     PISSN: 10105182     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcms.2008.06.003     Document Type: Article

References (48)

1. Al-Nawas B., Grötz K.A., Brahm R., Maeurer M., and Wagner W. Infektionen im Mund-, Kiefer- und Gesichtsbereich: was hat sich in den letzten 25 Jahren geändert?. DtschZahnärztlZ 55 (2000) 765-769
2. Aldridge K.E. Anaerobes in polymicrobial surgical infections: incidence, pathogenicity, and antimicrobial resistance. Eur J Surg Suppl (1994) 31-37
3. Appelbaum P.C. Comparative susceptibility profile of piperacillin/tazobactam against anaerobic bacteria. J Antimicrob Chemother 31 Suppl A (1993) 29-38
4. Boselli E., Breilh D., Biot L., Bel J.C., Saux M.C., and Allaouchiche B. Penetration of piperacillin/tazobactam into cancellous bone tissue. Curr Ther Res 62 (2001) 538-545
5. Boselli E., Breilh D., Cannesson M., Xuereb F., Rimmele T., Chassard D., Saux M.C., and Allaouchiche B. Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia. Intensive Care Med (2004)
6. Boselli E., Breilh D., Debon R., Duflo F., Bel J.C., Saux M.C., Chassard D., and Allaouchiche B. Penetration of piperacillin/tazobactam (4 g/500 mg) into synovial tissue. J Chemother 14 (2002) 54-58
7. Bourget P., Sertin A., Lesne-Hulin A., Fernandez H., Ville Y., and Van Peborgh P. Influence of pregnancy on the pharmacokinetic behaviour and the transplacental transfer of the piperacillin-tazobactam combination. Eur J Obstet Gynecol Reprod Biol 76 (1998) 21-27
8. Calhoun K.H., Shapiro R.D., Stiernberg C.M., Calhoun J.H., and Mader J.T. Osteomyelitis of the mandible. Arch Otolaryngol Head Neck Surg 114 (1988) 1157-1162
9. Dahlen G., Samuelsson W., Molander A., and Reit C. Identification and antimicrobial susceptibility of enterococci isolated from the root canal. Oral Microbiol Immunol 15 (2000) 309-312
10. Dalla Costa T., Nolting A., Rand K., and Derendorf H. Pharmacokinetic-pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations. Int J Clin Pharmacol Ther 35 (1997) 426-433
11. Duckworth C., Fisher J.F., Carter S.A., Newman C.L., Cogburn C., Nesbit R.R., and Wray C.H. Tissue penetration of clindamycin in diabetic foot infections. J Antimicrob Chemother 31 (1993) 581-584
12. Eick S., Pfister W., and Straube E. Antimicrobial susceptibility of anaerobic and capnophilic bacteria isolated from odontogenic abscesses and rapidly progressive periodontitis. Int J Antimicrob Agents 12 (1999) 41-46
13. Graham D.R., Lucasti C., Malafaia O., Nichols R.L., Holtom P., Perez N.Q., McAdams A., Woods G.L., Ceesay T.P., and Gesser R. Ertpenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicentre study. Clin Infect Dis 34 (2002) 1460-1468
14. Grimer R.J., Karpinski M.R., Andrews J.M., and Wise R. Penetration of amoxycillin and clavulanic acid into bone. Chemotherapy 32 (1986) 185-191
15. Hoellman D.B., Kelly L.M., Jacobs M.R., and Appelbaum P.C. In vitro anti-anaerobic activity of the cephalosporin derivative RWJ 54428, compared to seven other compounds. Clin Microbiol Infect 8 (2002) 814-822
16. Hudson J.W. Osteomyelitis of the jaws: a 50-year perspective. J Oral Maxillofac Surg 51 (1993) 1294-1301
17. Incavo S.J., Ronchetti P.J., Choi J.H., Wu H., Kinzig M., and Sörgel F. Penetration of piperacillin-tazobactam into cancellous and cortical bone tissues. AntimicrobAgents Chemother 38 (1994) 905-907
18. Johnson J.T., Kachman K., Wagner R.L., and Myers E.N. Comparison of ampicillin/sulbactam versus clindamycin in the prevention of infection in patients undergoing head and neck surgery. Head Neck 19 (1997) 367-371
19. Kato M., and Morimoto R. Concentration of piperacillin in bone. Jpn J Antibiot 37 (1984) 279-284
20. Kinzig M., Sörgel F., Brismar B., and Nord C.E. Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery. AntimicrobAgents Chemother 36 (1992) 1997-2004
21. Kononen E., Nyfors S., Matto J., and Asikainen S. Jousimies-Somer H: beta-lactamase production by oral pigmented Prevotella species isolated from young children. Clin Infect Dis 25 Suppl 2 (1997) S272-S274
22. Lewis M.A., Lamey P.J., and Gibson J. Quantitative bacteriology of a case of acute parotitis. Oral Surg Oral Med Oral Pathol 68 (1989) 571-575
23. Lewis M.A., Parkhurst C.L., Douglas C.W., Martin M.V., Absi E.G., Bishop P.A., and Jones S.A. Prevalence of penicillin resistant bacteria in acute suppurative oral infection. J Antimicrob Chemother 35 (1995) 785-791
24. Luthiger U. Clindamycin and penicillin V in the treatment of periodontal infections. A randomized study. Swiss Dent 4 (1983) 41-43
25. Malanchuk V.O., and Kopchak A.V. Risk factors for development of infection in patients with mandibular fractures located in the tooth-bearing area. J Craniomaxillofac Surg 35 (2007) 57-62
26. Mueller S.C., Henkel K.O., Neumann J., Hehl E.M., Gundlach K.K., and Drewelow B. Perioperative antibiotic prophylaxis in maxillofacial surgery: penetration of clindamycin into various tissues. J Craniomaxillofac Surg 27 (1999) 172-176
27. Mylonas A.I., Tzerbos F.H., Mihalaki M., Rologis D., and Boutsikakis I. Cerebral abscess of odontogenic origin. J Craniomaxillofac Surg 35 (2007) 63-67
28. Nicholas P., Meyers B.R., Levy R.N., and Hirschman S.Z. Concentration of clindamycin in human bone. Antimicrob Agents Chemother 8 (1975) 220-221
29. Pohlenz P., Blessmann M., Heiland M., Blake F., Schmelzle R., and Li L. Postoperative complications in 202 cases of microvascular head and neck reconstruction. J Craniomaxillofac Surg 35 (2007) 311-315
30. Reinhardt J.F., Johnston L., Ruane P., Johnson C.C., Ingram-drake L., MacDonald K., Ward K.W., Mathisen G., George W.L., Finegold S.M., et al. A randomized, double-blind comparison of sulbactam/ampicillin and clindamycin for the treatment of aerobic and aerobic-anaerobic infections. Rev Infect Dis 8 Suppl 5 (1986) S569-S575
31. Rissing J.P. Animal models of osteomyelitis. Knowledge, hypothesis, and speculation. Infect Dis Clin North Am 4 (1990) 377-390
32. Ryan D.M., and Cars O. A problem in the interpretation of beta-lactam antibiotic levels in tissues. J Antimicrob Chemother 12 (1983) 281-284
33. Schaumann R., Ackermann G., Pless B., Claros M.C., Goldstein E.J., and Rodloff A.C. In vitro activities of fourteen antimicrobial agents against obligately anaerobic bacteria. Int J Antimicrob Agents 16 (2000) 225-232
34. Siami F.S., LaFleur B.J., and Siami G.A. Clinafloxacin versus piperacillin/tazobactam in the treatment of severe skin and soft-tissue infections in adults at a Veterans Affairs medical center. Clin Ther 24 (2002) 59-72
35. Skitarelic N., Morovic M., and Manestar D. Antibiotic prophylaxis in clean-contaminated head and neck oncological surgery. J Craniomaxillofac Surg 35 (2007) 15-20
36. Smolka W., and Iizuka T. Surgical reconstruction of maxilla and midface: clinical outcome and factors relating to postoperative complications. J Craniomaxillofac Surg 33 (2005) 1-7
37. Snydman D.R., Jacobus N.V., McDermott L.A., Ruthazer R., Golan Y., Goldstein E.J., Finegold S.M., Harrell L.J., Hecht D.W., Jenkins S.G., Pierson C., Venezia R., Yu V., Rihs J., and Gorbach S.L. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004. Antimicrob Agents Chemother 51 (2007) 1649-1655
38. Sorensen T.S., Colding H., Schroeder E., and Rosdahl V.T. The penetration of cefazolin, erythromycin and methicillin into human bone tissue. Acta Orthop Scand 49 (1978) 549-553
39. Sörgel F., and Kinzig M. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J Antimicrob Chemother 31 Suppl A (1993) 39-60
40. Sörgel F., and Kinzig M. Pharmacokinetic characteristics of piperacillin/tazobactam. Intensive Care Med 20 Suppl 3 (1994) S14-S20
41. Sörgel F., and Kinzig M. Pharmacokinetics and tissue penetration of piperacillin/tazobactam with particular reference to its potential in abdominal and soft tissue infections. Eur J Surg Suppl (1994) 39-44
42. Spaey Y.J., Bettens R.M., Mommaerts M.Y., Adriaens J., Van Landuyt H.W., Abeloos J.V., De Clercq C.A., Lamoral P.R., and Neyt L.F. A prospective study on infectious complications in orthognathic surgery. J Craniomaxillofac Surg 33 (2005) 24-29
43. Tassler H. Therapie von Knochen- und Gelenkinfektionen mit Tazobactam/Piperacillin. Fortschritte der Antimikrobiellen und Antineoplastischen Chemotherapie 11 (1992) 525-534
44. Tomaselli F., Dittrich P., Maier A., Woltsche M., Matzi V., Pinter J., Nuhsbaumer S., Pinter H., Smolle J., and Smolle-Juttner F.M. Penetration of piperacillin and tazobactam into pneumonic human lung tissue measured by in vivo microdialysis. Br J Clin Pharmacol 55 (2003) 620-624
45. Trittler R., Ehrlich M., Galla T.J., Horch R.E., and Kummerer K. New and rapid fully automated method for determination of tazobactam and piperacillin in fatty tissue and serum by column-switching liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 775 (2002) 127-132
46. Wise R., Logan M., Cooper M., and Andrews J.M. Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin. Antimicrob Agents Chemother 35 (1991) 1081-1084
47. Witso E., Persen L., Loseth K., Benum P., and Bergh K. Cancellous bone as an antibiotic carrier. Acta Orthop Scand 71 (2000) 80-84
48. Young M., and Plosker G.L. Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections. Pharmacoeconomics 19 (2001) 1135-1175